Journal of Clinical Oncology, Vol 14, 2091-2097, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis

B Mellado, D Colomer, T Castel, M Munoz, E Carballo, M Galan, JM Mascaro, JL Vives-Corrons, JJ Grau and J Estape
Department of Medical Oncology, Hospital Clinic, University of Barcelona, Spain.

PURPOSE: Circulating melanoma cells can be detected in peripheral blood by means of tyrosinase mRNA amplification by reverse-transcriptase polymerase chain reaction (RT-PCR). We conducted a prospective study to evaluate the clinical significance of the presence of circulating neoplastic cells in the blood of patients with malignant melanoma (MM). METHODS: A sensitive RT-PCR assay was used to detect tyrosinase mRNA in the peripheral blood of patients with stages I to IV melanoma. Healthy subjects or patients with other malignancies were used as negative controls. RESULTS: Ninety-one assessable patients were included in the study. There was a statistically significant association between RT-PCR positivity and clinical stage. Circulating melanoma cells were detected in 36% of patients with localized disease (stages I and II), in 45% of patients with regional nodal involvement (stage III), and in 94% of patients with metastatic disease (stage IV) (P < .001). In stage II-III patients who were RT-PCR-positive for mRNA tyrosinase in blood, the recurrence rate and disease-free survival were significantly worse than patients who were RT-PCR-negative. In multivariate analysis, RT-PCR was an independent prognostic factor for recurrence in patients with nonmetastatic disease (P = .002). CONCLUSION: The detection of circulating melanoma cells in peripheral blood by RT-PCR correlated with the clinical stage of patients with melanoma and was an independent prognostic factor for recurrence. Further studies are warranted to better assess the significance of this test in the evaluation of prognosis, early detection of relapse, and in monitoring the effectiveness of systemic therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Schuster, N. E. Bechrakis, A. Stroux, A. Busse, A. Schmittel, C. Scheibenbogen, E. Thiel, M. H. Foerster, and U. Keilholz Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma Clin. Cancer Res., February 15, 2007; 13(4): 1171 - 1178. [Abstract] [Full Text] [PDF]

				S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis Clin. Cancer Res., August 1, 2006; 12(15): 4605 - 4613. [Abstract] [Full Text] [PDF]

				C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857. [Abstract] [Full Text] [PDF]

				P. L. Blanco, J. C. A. Marshall, E. Antecka, S. A. Callejo, J. P. Souza Filho, V. Saraiva, and M. N. Burnier Jr Characterization of Ocular and Metastatic Uveal Melanoma in an Animal Model Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4376 - 4382. [Abstract] [Full Text] [PDF]

				C. Voit, M. Kron, J. Rademaker, M. Schwurzer-Voit, W. Sterry, L. Weber, C. Ozdemir, T. Proebstle, and U. Keilholz Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival J. Clin. Oncol., February 20, 2005; 23(6): 1218 - 1227. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]

				R. S. Faye, S. Aamdal, H. K. Hoifodt, E. Jacobsen, L. Holstad, E. Skovlund, and O. Fodstad Immunomagnetic Detection and Clinical Significance of Micrometastatic Tumor Cells in Malignant Melanoma Patients Clin. Cancer Res., June 15, 2004; 10(12): 4134 - 4139. [Abstract] [Full Text] [PDF]

				J. Szenajch, B. Jasinski, A. Synowiec, J. Kulik, M. Chomicka, J. Struzyna, Z. Nowecki, P. Rutkowski, W. Ruka, W. Kupsc, et al. Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma Clin. Chem., September 1, 2003; 49(9): 1450 - 1457. [Abstract] [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, F. Perrone, S. M.R. Satriano, A. Ottaiano, A. Daponte, M. Napolitano, C. Caraco, N. Mozzillo, M. T. Melucci, et al. Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction J. Clin. Oncol., March 1, 2003; 21(5): 767 - 773. [Abstract] [Full Text] [PDF]

				B. Mellado, M. del Carmen Vela, D. Colomer, L. Gutierrez, T. Castel, L. Quinto, M. Fontanillas, N. Reguart, J. M. Domingo-Domenech, C. Montagut, et al. Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon J. Clin. Oncol., October 1, 2002; 20(19): 4032 - 4039. [Abstract] [Full Text] [PDF]

				S. Yokoyama and H. Yamaue Prediction of Distant Metastasis by Using Reverse Transcriptase-Polymerase Chain Reaction for Epithelial and Variant CD44 mRNA in the Peripheral Blood of Patients With Colorectal Cancer Arch Surg, September 1, 2002; 137(9): 1069 - 1073. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. Ozawa, N. Ando, Y. Kitagawa, M. Ueda, and M. Kitajima Clinical significance of telomerase activity in peripheral blood of patients with esophageal squamous cell carcinoma Ann. Thorac. Surg., March 1, 2002; 73(3): 927 - 932. [Abstract] [Full Text] [PDF]

				U. Reinhold, C. Berkin, A.-K. Bosserhoff, A. Deutschmann, C. Garbe, R. Glaser, R. Hein, G. Krahn, R. U. Peter, G. Rappl, et al. Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction-Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group J. Clin. Oncol., March 15, 2001; 19(6): 1723 - 1727. [Abstract] [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, A. Cossu, N. Mozzillo, M. L. Motti, S. M.R. Satriano, G. Botti, C. Caraco, E. Celentano, R. A. Satriano, et al. Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay J. Clin. Oncol., March 1, 2001; 19(5): 1437 - 1443. [Abstract] [Full Text] [PDF]

				H. Tsao, U. Nadiminti, A. J. Sober, and M. Bigby A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma Arch Dermatol, March 1, 2001; 137(3): 325 - 330. [Abstract] [Full Text] [PDF]

				E. D. Martenson, L.O. Hansson, B. Nilsson, E. von Schoultz, E. M. Brahme, U. Ringborg, and J. Hansson Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous Melanoma J. Clin. Oncol., February 1, 2001; 19(3): 824 - 831. [Abstract] [Full Text] [PDF]

				J. M. Karjalainen, R. H. Tammi, M. I. Tammi, M. J. Eskelinen, U. M. Agren, J. J. Parkkinen, E. M. Alhava, and V.-M. Kosma Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma Am. J. Pathol., September 1, 2000; 157(3): 957 - 965. [Abstract] [Full Text] [PDF]

				J.-J. Lu, Y. Kakehi, T. Takahashi, X.-X. Wu, T. Yuasa, T. Yoshiki, Y. Okada, T. Terachi, and O. Ogawa Detection of Circulating Cancer Cells by Reverse Transcription-Polymerase Chain Reaction for Uroplakin II in Peripheral Blood of Patients with Urothelial Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3166 - 3171. [Abstract] [Full Text]

				D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence Cancer Res., April 1, 2000; 60(8): 2253 - 2257. [Abstract] [Full Text]

				P. J. Bostick, D. L. Morton, R. R. Turner, K. T. Huynh, H.-J. Wang, R. Elashoff, R. Essner, and D. S.B. Hoon Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase–Polymerase Chain Reaction in Early-Stage Melanoma Patients J. Clin. Oncol., October 1, 1999; 17(10): 3238 - 3244. [Abstract] [Full Text] [PDF]

				B. J. Curry, K. Myers, and P. Hersey MART-1 Is Expressed Less Frequently on Circulating Melanoma Cells in Patients Who Develop Distant Compared With Locoregional Metastases J. Clin. Oncol., August 1, 1999; 17(8): 2562 - 2562. [Abstract] [Full Text] [PDF]

				R. A. Ghossein, S. Bhattacharya, and J. Rosai Molecular Detection of Micrometastases and Circulating Tumor Cells in Solid Tumors Clin. Cancer Res., August 1, 1999; 5(8): 1950 - 1960. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, N.-K. V. Cheung, R. A. Ghossein, J. M. Satagopan, S. Bhattacharya, and D. G. Coit Association between Molecular Detection of GAGE and Survival in Patients with Malignant Melanoma: A Retrospective Cohort Study Clin. Cancer Res., August 1, 1999; 5(8): 2042 - 2047. [Abstract] [Full Text] [PDF]

				B. Mellado, L. Gutierrez, T. Castel, D. Colomer, M. Fontanillas, J. Castro, and J. Estape Prognostic Significance of the Detection of Circulating Malignant Cells by Reverse Transcriptase-Polymerase Chain Reaction in Long-Term Clinically Disease-free Melanoma Patients Clin. Cancer Res., July 1, 1999; 5(7): 1843 - 1848. [Abstract] [Full Text] [PDF]

				C.-J. Tseng, C. C. Pao, J.-D. Lin, Y.-K. Soong, J.-H. Hong, and S. Hsueh Detection of Human Papillomavirus Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association With Prognosis J. Clin. Oncol., May 1, 1999; 17(5): 1391 - 1391. [Abstract] [Full Text] [PDF]

				M. Muhlbauer, N. Langenbach, W. Stolz, R. Hein, M. Landthaler, R. Buettner, and A.-K. Bosserhoff Detection of Melanoma Cells in the Blood of Melanoma Patients by Melanoma-inhibitory Activity (MIA) Reverse Transcription-PCR Clin. Cancer Res., May 1, 1999; 5(5): 1099 - 1105. [Abstract] [Full Text] [PDF]

				G. Palmieri, M. Strazzullo, P. A. Ascierto, S. M.R. Satriano, A. Daponte, and G. Castello Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression J. Clin. Oncol., January 1, 1999; 17(1): 304 - 304. [Abstract] [Full Text] [PDF]

				W. Dietmaier, A. Hartmann, S. Wallinger, E. Heinmoller, T. Kerner, E. Endl, K.-W. Jauch, F. Hofstadter, and J. Ruschoff Multiple Mutation Analyses in Single Tumor Cells with Improved Whole Genome Amplification Am. J. Pathol., January 1, 1999; 154(1): 83 - 95. [Abstract] [Full Text] [PDF]

				M. Piepkorn, M. A. Weinstock, and R. L. Barnhill Theoretical and Empirical Arguments in Relation to Elective Lymph Node Dissection for Melanoma Arch Dermatol, August 1, 1997; 133(8): 995 - 1002. [Abstract] [PDF]

				R. Halaban, E. Cheng, Y. Zhang, G. Moellmann, D. Hanlon, M. Michalak, V. Setaluri, and D. N. Hebert Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells PNAS, June 10, 1997; 94(12): 6210 - 6215. [Abstract] [Full Text] [PDF]